AstraZeneca's Tagrisso Secures EU Approval for New Lung Cancer Application

AstraZeneca has announced a significant breakthrough in its oncology portfolio as its lung cancer medication, Tagrisso, has received approval from the European Union for an additional indication. This landmark decision allows Tagrisso, which is primarily used to treat non-small cell lung cancer (NSCLC), to be administered for patients with early-stage lung cancer who are at a higher risk of disease recurrence following surgery.

Continue reading